Plasma proteomics-based biomarkers for predicting response to mesenchymal stem cell therapy in severe COVID-19

Table 2 Up-/down-regulated differentially expressed proteins (DEPs) between the responders and non-responders pre-MSC treatment

Protein names	UniprotKB	Gene names	Mean (responders)	Mean (non-responders)	p	Up-/down-regulated
CSPG2	P13611	VCAN	15.481	14.252	0.031	Up
CTRB1	P17538	CTRB1	15.494	14.540	0.024	Up
OSCAR	Q8IYS5	OSCAR	14.718	13.254	0.025	Up
ANXA1	P04083	ANXA1	15.973	17.200	0.005	Down
AGRG6	Q86SQ4	ADGRG6	16.955	17.639	0.016	Down
CAPG	P40121	CAPG	13.617	14.336	0.040	Down
DDX55	Q8NHQ9	DDX55	17.657	19.497	0.002	Down
KV133	P01593	IGKV1-33	20.221	21.109	0.016	Down
LEG10	Q05315	CLC	15.315	16.517	0.009	Down
OXSR1	O95747	OXSR1	12.997	14.154	0.002	Down
PICAL	Q13492	PICALM	20.039	21.127	0.042	Down
PTGDS	P41222	PTGDS	17.964	18.867	0.045	Down
S100A8	P05109	S100A8	21.790	22.381	0.044	Down

Differentially expressed proteins (DEPs) are defined as those proteins with a fold change (FC) > 1.5 or FC < 1/1.5 and p < 0.05 between the responders and non-responders. Upregulated proteins in the responders compared with that in the non-responders, fold change (FC) > 1.5 and p < 0.05. Downregulated proteins in the responders compared with that in the non-responders, FC < 1/1.5 and p < 0.05. Words highlighted in bold indicate that the five proteins identified in the final logistic regression model

ISSN: 1757-6512